Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sch-23390. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 13/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sch-23390 SCHEMBL30192744 | 1.00 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL1774187 | 1.00 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL7202762 | 1.00 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL29797998 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL11107859 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL16187032 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL2916216 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL29431888 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL29424268 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR | |
| Sch-23390 SCHEMBL30628012 | 0.99 | DRD1 (1.00) | DRD1LMNAADRB2GPR183APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022647-A1 | COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE | KNOPP BIOSCIENCES LLC (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2015019347-A1 | GIRK AS A THERAPEUTIC TARGET OF IMMUNE DISORDERS AND A MARKER OF B CELL SUBTYPES | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2015-02-12 | — | — | WO | disclosed |
| US-20130230569-A1 | COMPOSITIONS OF R(+) AND S(-) PRAMIPEXOLE AND METHODS OF USING THE SAME | KNOPP NEUROSCIENCES, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445474-B2 | Compositions of R(+) and S(−) pramipexole and methods of using the same | KNOPP NEUROSCIENCES, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130123312-A1 | Compositions and Methods of Using R(+) Pramipexole | KNOPP NEUROSCIENCES INC. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2497473-A1 | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof | Knopp Neurosciences, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2497472-A1 | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions | Knopp Neurosciences, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225915-A1 | Compositions and Methods of Using R(+) Pramipexole | KNOPP NEUROSCIENCES INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2465500-A1 | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease | Knopp Neurosciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110293718-A1 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same | KNOPP NEUROSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2026803-A2 | COMPOSITIONS OF R(+) AND S(-) PRAMIPEXOLE AND METHODS OF USING THE SAME | Knopp Neurosciences, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1921989-A2 | NEURONAL AVALANCHE ASSAY | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080027651-A1 | Methods and Systems for Drug Screening and Computational Modeling Based on Biologically Realistic Neurons | MCLEAN HOSPITAL CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080014259-A1 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same | KNOPP NEUROSCIENCES, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| WO-2007137071-A2 | COMPOSITIONS OF R(+) AND S(-) PRAMIPEXOLE AND METHODS OF USING THE SAME | KNOPP NEUROSCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070259930-A1 | COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE | KNOPP NEUROSCIENCES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007022208-A2 | NEURONAL AVALANCHE ASSAY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060089824-A1 | Methods and systems for drug screening and computational modeling | SIEKMEIER PETER | 2006-04-27 | — | — | US | disclosed |
| WO-2003101282-A2 | METHODS AND SYSTEMS FOR DRUG SCREENING AND COMPUTATIONAL MODELING | MCLEAN HOSPITAL CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| US-5571823-A | ADMINISTERING A DOPAMINE ANTAGONIST | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230569-A1 | COMPOSITIONS OF R(+) AND S(-) PRAMIPEXOLE AND METHODS OF USING THE SAME | SNCA, PARK7, COMT | DRD1 498/4885ADRB2 78/4885DRD2 238/4885 |
| US-20070259930-A1 | COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE | CKMT1A; CKMT1B, ARG2, NLN | DRD1 3606/4885ADRB2 359/4885DRD2 3101/4885 |
| US-20130123312-A1 | Compositions and Methods of Using R(+) Pramipexole | CKMT1A; CKMT1B, ARG2, NLN | DRD1 3606/4885ADRB2 359/4885DRD2 3101/4885 |
| US-20080014259-A1 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same | SNCA, PARK7, COMT | DRD1 498/4885ADRB2 78/4885DRD2 238/4885 |
| US-20160022647-A1 | COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE | CKMT1A; CKMT1B, ARG2, NLN | DRD1 3606/4885ADRB2 359/4885DRD2 3101/4885 |
| US-20110293718-A1 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same | SNCA, PARK7, COMT | DRD1 498/4885ADRB2 78/4885DRD2 238/4885 |
| US-20120225915-A1 | Compositions and Methods of Using R(+) Pramipexole | CKMT1A; CKMT1B, ARG2, NLN | DRD1 3606/4885ADRB2 359/4885DRD2 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.